| Date | Time | Source | Headline | Symbol | Company |
| 03/08/2024 | 4:49PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 03/01/2024 | 4:40PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 03/01/2024 | 7:35AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/29/2024 | 8:23PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/29/2024 | 4:44PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/29/2024 | 8:09AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/14/2024 | 5:09PM | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/13/2024 | 3:53PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/13/2024 | 8:50AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/12/2024 | 1:38PM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/09/2024 | 5:45AM | PR Newswire (US) | Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/07/2024 | 9:15AM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/06/2024 | 5:09PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 02/02/2024 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/26/2024 | 11:49AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/26/2024 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/19/2024 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/18/2024 | 6:56AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/18/2024 | 6:50AM | GlobeNewswire Inc. | Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/16/2024 | 7:00AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/12/2024 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/09/2024 | 5:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/09/2024 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 01/05/2024 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/22/2023 | 7:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/22/2023 | 5:15PM | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/20/2023 | 4:34PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/18/2023 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/15/2023 | 5:11PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 12/06/2023 | 4:26PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |